hiv-1 & coronavirus-coinfection in europe: morbidity & risk factors of covid-19 in people living with hiv

Conditions: HIV-1-infection; COVID-19

Summary: hiv coco is a european multi-centre, multi-country, retrospective, observational case-control study that will aim to describe clinical outcomes and identify risk factors for people living with hiv (plwhiv) who are co-infected with the sars-cov-2 coronavirus. the study will address two central questions: 1. is there a particular risk for covid-19 in plwhiv as compared to hiv seronegative control covid-19 cases? 2. are there particular factors, within the group of plwhiv, which put them at risk for a more severe covid-19 disease course? the study will address these questions by recruiting patients co-infected with both hiv and sars-cov-2 and comparing them to two control groups - one group infected with sars-cov-2 only and another group infected with hiv only. only deidentified, real-world retrospective data will be used for the study, collected as part of standard, routine clinical care. additionally, this study will also look to: 1. describe the differences in the clinical manifestation of covid-19 in plwhiv compared to hiv seronegative controls 2. describe the response to treatment, including supportive care and novel therapies against covid-19, including antiviral or immunomodulatory therapy 3. describe the co-morbidities in plwhiv and controls with covid-19 4. compare the severity of covid-19 between plwhiv and the covid-19 only controls at diagnosis and hospital admission. data will be collected about patient outcomes from covid-19 (including hospitalisation for covid-19, length of stay in hospital, critical care admission, ventilation/oxygenation requirements, and need for kidney replacement therapy), as well as pre-existing health conditions, and relevant blood results at covid-19 diagnosis.


Eligibility criteria:
inclusion criteria: * • cases (plwhiv + covid-19) 1. any gender 2. at least 18 years of age 3. documented hiv-1 infection 4. confirmed sars-cov-2 infection by documented, or patient-reported, positive result on pcr testing of a nasopharyngeal or respiratory sample, before 1st april 2021 * controls (covid-19) 1. any gender 2. at least 18 years of age 3. no documented hiv-1 infection 4. confirmed sars-cov-2 infection by documented, or patient-reported, positive result on pcr testing of a nasopharyngeal or respiratory sample, before 1st april 2021 5. meet the matching criteria for comparing plwhiv \& covid-19 versus hiv seronegative covid-19 patients, a 1:1 matching will be performed according to the following criteria: * age (+/- 5 years) * sex * ethnicity (where available) * month of covid-19 diagnosis (+/- 2 months) * covid-19 diagnosis inpatient or * covid-19 diagnosis outpatient (ambulatory) * controls (plwhiv) 1. any gender 2. at least 18 years of age 3. documented hiv-1 infection 4. no evidence of sars-cov-2 infection 5. meet the matching criteria for comparing plwhiv \& covid-19 versus plwhiv without covid-19, a 1:2 matching for similar risk of acquiring covid-19 will be performed according to the following criteria: * age (+/- 5 years) * sex * ethnicity (where available) exclusion criteria for cases (plwhiv + covid-19) and for covid-19 only controls: * covid-19 diagnosed based on clinical criteria